Genmab A/S Forecast, price target & analysts
Genmab A/S Target price 2026 - Analyst rating & recommendation
Genmab A/S Classifications & Recommendation:
Genmab A/S Price Target
| Target Price | kr2,142.00 |
| Price | kr2,007.00 |
| Potential |
6.73%
register free of charge
|
| Number of Estimates | 19 |
|
19 Analysts have issued a price target Genmab A/S 2027 .
The average Genmab A/S target price is kr2,142.00.
This is
6.73%
register free of charge
kr3,213.00
60.09%
register free of charge
kr1,025.15
48.92%
register free of charge
|
|
| A rating was issued by 27 analysts: 17 Analysts recommend Genmab A/S to buy, 8 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Genmab A/S stock has an average upside potential 2027 of
6.73%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion kr | 3.12 | 3.73 |
| 30.57% | 19.51% | |
| EBITDA Margin | 34.33% | 38.52% |
| 4.33% | 12.20% | |
| Net Margin | 36.44% | 29.72% |
| 37.94% | 18.44% |
25 Analysts have issued a sales forecast Genmab A/S 2025 . The average Genmab A/S sales estimate is
This results in the following potential growth metrics:
17 Analysts have issued an Genmab A/S EBITDA forecast 2025. The average Genmab A/S EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
24 Genmab A/S Analysts have issued a net profit forecast 2025. The average Genmab A/S net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share kr | 17.60 | 18.01 |
| 83.72% | 2.33% | |
| P/E | 111.44 | |
| EV/Sales | 32.58 |
24 Analysts have issued a Genmab A/S forecast for earnings per share. The average Genmab A/S EPS is
This results in the following potential growth metrics and future valuations:
Current Genmab A/S Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| TRUIST SECURITIES |
Locked
➜
Locked
|
Locked | Dec 11 2025 |
| TD COWEN |
Locked
➜
Locked
|
Locked | Dec 08 2025 |
| NYKREDIT MARKETS |
Locked
➜
Locked
|
Locked | Dec 05 2025 |
| JYSKE BANK |
Locked
➜
Locked
|
Locked | Dec 01 2025 |
| HANDELSBANKEN CAPITAL MARKETS |
Locked
➜
Locked
|
Locked | Nov 21 2025 |
| H.C. WAINWRIGHT & CO., LLC |
Locked
➜
Locked
|
Locked | Nov 19 2025 |
| ROTHSCHILD & CO REDBURN |
Locked
➜
Locked
|
Locked | Nov 17 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
TRUIST SECURITIES:
Locked
➜
Locked
|
Dec 11 2025 |
|
Locked
TD COWEN:
Locked
➜
Locked
|
Dec 08 2025 |
|
Locked
NYKREDIT MARKETS:
Locked
➜
Locked
|
Dec 05 2025 |
|
Locked
JYSKE BANK:
Locked
➜
Locked
|
Dec 01 2025 |
|
Locked
HANDELSBANKEN CAPITAL MARKETS:
Locked
➜
Locked
|
Nov 21 2025 |
|
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
➜
Locked
|
Nov 19 2025 |
|
Locked
ROTHSCHILD & CO REDBURN:
Locked
➜
Locked
|
Nov 17 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
